CVM
CEL-SCI Corporation
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Buy
+22/100
Last price
2.21
▼ 0.53 (19.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.87
Prev close
2.74
Day high
2.77
Day low
2.21
Volume
336.10K
Market cap
$38.96M
P/E (TTM)
—
52W range
0.89 – 10.62
Day trading desk
Gap from prior close
+4.78%
Prior close 2.74
VWAP
2.51
-11.84% from price
Relative volume
1.39×
Normal
Session range
29.90%
2.21 – 2.87
Position in range
1%
Near session low
ATR (14D)
0.23
10.29% of price
Prior day high
2.83
PDH
Prior day low
2.29
PDL
Bid / ask spread
—
Quote not published
Session volume
329.58K
Avg 236.35K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+7.52%
+6.0%
1M
+34.24%
+33.1%
3M
+64.07%
+61.0%
6M
-49.54%
-64.1%
YTD
-57.89%
-71.5%
1Y
-78.07%
-93.4%
3Y
-93.64%
-174.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CVM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
653.43K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | KERSTEN GEERT R Chief Executive Officer |
STOCK | 2.62K | $5.40K | Direct |
| Sep 30, 26 | TALOR EYAL Officer |
STOCK | 1.17K | $2.40K | Direct |
| Aug 25, 26 | KERSTEN GEERT R Chief Executive Officer |
BUY | 100.00K | $138.00K | Direct |
| Jun 30, 26 | KERSTEN GEERT R Chief Executive Officer |
STOCK | 5.19K | $5.40K | Direct |
| Jun 30, 26 | TALOR EYAL Officer |
STOCK | 2.31K | $2.40K | Direct |
| Jun 30, 26 | PRICHEP PATRICIA B Chief Financial Officer |
STOCK | 4.13K | $4.29K | Direct |
| May 14, 26 | KERSTEN GEERT R Chief Executive Officer |
BUY | 300.00K | $360.00K | Indirect |
| May 13, 26 | KERSTEN GEERT R Chief Executive Officer |
BUY | 100.00K | $119.00K | Direct |
| Mar 31, 26 | KERSTEN GEERT R Chief Executive Officer |
STOCK | 1.68K | $5.40K | Direct |
| Mar 31, 26 | TALOR EYAL Officer |
STOCK | 747 | $2.40K | Direct |
| Mar 31, 26 | PRICHEP PATRICIA B Chief Financial Officer |
STOCK | 1.34K | $4.29K | Direct |
| Jan 22, 26 | KERSTEN GEERT R Chief Executive Officer |
BUY | 38.02K | $200.00K | Direct |
| Dec 31, 25 | KERSTEN GEERT R Chief Executive Officer |
STOCK | 998 | $5.25K | Direct |
| Dec 31, 25 | TALOR EYAL Officer |
STOCK | 456 | $2.40K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
KERSTEN GEERT R |
Chief Executive Officer | 630.31K | Stock Award(Grant) |
PRICHEP PATRICIA B |
Chief Financial Officer | 17.49K | Stock Award(Grant) |
TALOR EYAL |
Officer | 10.48K | Stock Award(Grant) |
WATSON ROBERT EUGENE |
Director | 3.73K | Purchase |
Fundamentals
Market cap$38.96M
Enterprise value$49.56M
Revenue (TTM)—
Gross profit$-14.80M
EBITDA$-20.26M
Net income$-22.70M
EPS (TTM)$-1.69
Free cash flow$-8.91M
Total cash$6.54M
Total debt$7.90M
Book value / share$0.62
Shares outstanding17.59M
Float16.92M
Short % of float3.63%
Dividend yield0.00%
Beta (5Y)0.59
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.35
PEG ratio1.12
Price / sales—
Price / book3.56
EV / revenue—
EV / EBITDA-2.45
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-252.53%
Return on assets-66.82%
Debt / equity72.10
Current ratio1.48
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $15.89M | $18.16M | $22.47M | $25.36M | -12.5% |
| Selling, general & admin | $8.92M | $8.19M | $9.00M | $10.71M | +8.9% |
| Total operating expense | $24.81M | $26.35M | $31.48M | $36.06M | -5.9% |
| Operating income | -$24.81M | -$26.35M | -$31.48M | -$36.06M | +5.9% |
| Net interest income | -$648.94K | -$745.67K | -$675.42K | -$1.08M | +13.0% |
| Pre-tax income | -$25.41M | -$26.92M | -$32.19M | -$36.70M | +5.6% |
| Net income | -$25.41M | -$26.92M | -$32.19M | -$36.70M | +5.6% |
| Net income to common | -$25.41M | -$27.58M | -$32.37M | -$37.63M | +7.9% |
| Basic EPS | -6.27 | -15.31 | -21.90 | -26.10 | +59.0% |
| Diluted EPS | -6.27 | -15.31 | -21.90 | -26.10 | +59.0% |
| EBIT | -$24.76M | -$26.17M | -$31.52M | -$35.62M | +5.4% |
| EBITDA | -$20.88M | -$22.21M | -$27.56M | -$31.79M | +6.0% |
| Basic shares | 4.06M | 1.80M | 1.48M | 1.44M | +125.1% |
| Diluted shares | 4.06M | 1.80M | 1.48M | 1.44M | +125.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $10.95M | $4.74M | $4.15M | $22.67M | +131.2% |
| Cash & short-term investments | $10.95M | $4.74M | $4.15M | $22.67M | +131.2% |
| Accounts receivable | — | — | — | $0 | — |
| Inventory | $303.28K | $1.02M | $2.25M | $2.00M | -70.3% |
| Total current assets | $11.60M | $6.06M | $6.92M | $25.44M | +91.5% |
| Property, plant & equipment | $12.90M | $16.98M | $21.02M | $24.71M | -24.0% |
| Goodwill & intangibles | $119.86K | $165.49K | $197.70K | $212.20K | -27.6% |
| Total assets | $28.16M | $26.99M | $30.53M | $50.52M | +4.3% |
| Total current liabilities | $5.13M | $4.62M | $5.59M | $4.66M | +11.2% |
| Total debt | $9.38M | $11.62M | $13.57M | $15.30M | -19.3% |
| Total liabilities | $12.20M | $14.12M | $17.31M | $18.36M | -13.6% |
| Retained earnings | -$539.42M | -$514.01M | -$487.09M | -$454.90M | -4.9% |
| Shareholder equity | $15.96M | $12.87M | $13.21M | $32.16M | +24.0% |
| Working capital | $6.47M | $1.44M | $1.33M | $20.77M | +349.0% |
| Net tangible assets | $15.84M | $12.70M | $13.02M | $31.95M | +24.7% |
| Shares issued | 8.02M | 2.13M | 1.58M | 1.45M | +277.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$25.41M | -$26.92M | -$32.19M | -$36.70M | +5.6% |
| Depreciation & amortisation | $3.89M | $3.97M | $3.96M | $3.83M | -2.1% |
| Stock-based compensation | $2.88M | $5.35M | $7.15M | $12.38M | -46.1% |
| Change in working capital | $1.16M | -$1.21M | -$1.78M | $2.48M | +195.6% |
| Operating cash flow | -$17.12M | -$18.81M | -$22.85M | -$18.24M | +9.0% |
| Capital expenditure | -$38.11K | -$108.09K | -$372.26K | -$660.63K | +64.7% |
| Investing cash flow | -$38.11K | -$108.09K | -$372.26K | $5.49M | +64.7% |
| Financing cash flow | $23.37M | $19.51M | $4.69M | -$638.43K | +19.8% |
| Free cash flow | -$17.16M | -$18.92M | -$23.22M | -$18.90M | +9.3% |
| End cash position | $10.95M | $4.74M | $4.15M | $22.67M | +131.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $3.65M | $3.77M | $3.68M | $3.70M | $3.74M | — | -3.1% |
| Selling, general & admin | $1.91M | $1.56M | $1.69M | $2.33M | $1.75M | — | +22.3% |
| Total operating expense | $5.56M | $5.33M | $5.37M | $6.03M | $5.49M | — | +4.3% |
| Operating income | -$5.56M | -$5.33M | -$5.37M | -$6.03M | -$5.49M | — | -4.3% |
| Net interest income | -$110.24K | -$117.48K | -$87.79K | -$128.50K | -$172.05K | — | +6.2% |
| Pre-tax income | -$5.67M | -$5.47M | -$5.47M | -$6.10M | -$5.66M | — | -3.7% |
| Net income | -$5.67M | -$5.47M | -$5.47M | -$6.10M | -$5.66M | — | -3.7% |
| Net income to common | -$5.67M | -$5.47M | -$5.47M | -$6.10M | -$5.66M | — | -3.7% |
| Basic EPS | -0.47 | -0.67 | -0.68 | — | -1.36 | -2.33 | +29.9% |
| Diluted EPS | -0.47 | -0.67 | -0.68 | — | -1.36 | -2.33 | +29.9% |
| EBIT | -$5.56M | -$5.35M | -$5.38M | -$5.97M | -$5.49M | — | -3.9% |
| EBITDA | -$4.61M | -$4.39M | -$4.42M | -$5.01M | -$4.53M | — | -5.0% |
| Basic shares | 12.12M | 8.14M | 8.02M | — | 4.15M | 2.82M | +48.9% |
| Diluted shares | 12.12M | 8.14M | 8.02M | — | 4.15M | 2.82M | +48.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.53M | $1.89M | $6.28M | $10.95M | $1.79M | +245.2% |
| Cash & short-term investments | $6.53M | $1.89M | $6.28M | $10.95M | $1.79M | +245.2% |
| Inventory | $266.76K | $281.46K | $230.45K | $303.28K | $518.04K | -5.2% |
| Total current assets | $7.50M | $2.89M | $7.03M | $11.60M | $2.62M | +159.3% |
| Property, plant & equipment | $10.22M | $11.21M | $12.21M | $12.90M | $13.91M | -8.8% |
| Goodwill & intangibles | $69.69K | $73.33K | $101.55K | $119.86K | $130.59K | -5.0% |
| Total assets | $21.36M | $17.71M | $22.89M | $28.16M | $20.34M | +20.6% |
| Total current liabilities | $5.08M | $4.81M | $5.04M | $5.13M | $5.62M | +5.7% |
| Total debt | $7.90M | $8.51M | $9.11M | $9.38M | $9.96M | -7.2% |
| Total liabilities | $10.40M | $10.83M | $11.76M | $12.20M | $13.31M | -4.0% |
| Retained earnings | -$556.03M | -$550.36M | -$544.89M | -$539.42M | -$533.32M | -1.0% |
| Shareholder equity | $10.96M | $6.87M | $11.14M | $15.96M | $7.02M | +59.4% |
| Working capital | $2.42M | -$1.91M | $1.99M | $6.47M | -$2.99M | +226.7% |
| Net tangible assets | $10.89M | $6.80M | $11.04M | $15.84M | $6.89M | +60.1% |
| Shares issued | 17.59M | 8.49M | 8.42M | 8.02M | 5.32M | +107.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$5.67M | -$5.47M | -$5.47M | -$6.10M | -$5.66M | -3.7% |
| Depreciation & amortisation | $946.37K | $956.40K | $964.42K | $960.85K | $959.01K | -1.0% |
| Stock-based compensation | $670.38K | $570.27K | $558.86K | $661.70K | $207.29K | +17.6% |
| Change in working capital | $7.79K | -$556.79K | -$139.22K | -$194.29K | $557.03K | +101.4% |
| Operating cash flow | -$4.03M | -$4.02M | -$4.02M | -$4.67M | -$3.94M | -0.2% |
| Capital expenditure | — | — | — | -$5.16K | — | — |
| Investing cash flow | $0 | $0 | $0 | -$5.16K | $0 | — |
| Financing cash flow | $8.67M | -$364.46K | -$653.77K | $13.84M | $3.81M | +2,478.3% |
| Free cash flow | -$4.03M | -$4.02M | -$4.02M | -$4.68M | -$3.94M | -0.2% |
| End cash position | $6.53M | $1.89M | $6.28M | $10.95M | $1.79M | +245.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | -3.07 | 1 | $0 | 0.0% |
| Next year | -6.38 | 1 | $5.97M | 0.0% |
Analyst targets & ownership
Mean target$12.50
High target$15.00
Low target$10.00
Implied upside464.33%
Analyst count2
ConsensusNONE
Strong buy / Buy1 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders3.72%
Held by institutions14.63%
Institutions holding48
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.07
+6.93% from price
SMA 20
1.82
+21.69% from price
SMA 50
1.63
+35.88% from price
SMA 100
1.45
+53.21% from price
SMA 200
2.82
-21.41% from price
EMA 12
2.09
+5.91% from price
EMA 26
1.87
+18.59% from price
EMA 50
1.72
+28.42% from price
RSI (14)
61.1
Neutral
MACD (12,26,9)
0.22
Hist 0.08
ATR (14)
0.23
10.29% of price
Realised vol 30D
100.9%
Annualised
Bollinger upper
2.53
20, 2σ
Bollinger lower
1.11
20, 2σ
50 / 200 cross
Death
1.63 vs 2.82
Trend bias
Below 200
-21.41%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.63
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
100.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-90.5%
Peak to trough
Max drawdown 5Y
-99.7%
Peak to trough
ATR 14
0.23
10.29% of price
Beta (reported)
0.59
5Y monthly, from filing
Short interest
Shares short
619.26K
Prior 714.47K
Change vs prior
-13.3%
Shorts covering
% of float
3.63%
Normal
% of shares out
3.52%
Against total outstanding
Days to cover
4.7
Liquid
Float
16.92M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 12, 23 | EF Hutton | MAINTAINED | Buy | Buy |
| Mar 9, 23 | EF Hutton | MAINTAINED | — | Buy |
| Dec 29, 22 | EF Hutton | MAINTAINED | — | Buy |
| Apr 7, 22 | EF Hutton | INITIATED | — | Buy |
| Jan 13, 20 | HC Wainwright & Co. | INITIATED | — | Buy |
| Feb 20, 13 | Taglich Brothers | INITIATED | — | Speculative Buy |
| Feb 13, 13 | Chardan Capital | INITIATED | — | Buy |
| Jan 14, 13 | Laidlaw & Co. | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend dateAug 28, 1996
Next pay dateJun 15, 2017
Last split1:30
Split dateMay 20, 2025
SEC filings
Offering Registrations
S-8 · 2026-09-03
Corporate Changes & Voting Matters
8-K · 2026-08-17
Periodic Financial Reports
10-Q · 2026-08-14
Proxy Statements
DEF 14A · 2026-07-02
Corporate Changes & Voting Matters
8-K · 2026-06-16
Registration Withdrawal Request
RW · 2026-05-27
Registration Withdrawal Request
RW · 2026-05-19
Periodic Financial Reports
10-Q · 2026-05-15
Headlines
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
Business Wire · 22d ago
CEL-SCI Reports Fiscal Third Quarter 2026 Results
Business Wire · 51d ago
Cel-Sci: Fiscal Q3 Earnings Snapshot
Associated Press · 54d ago
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
Business Wire · 64d ago
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
Business Wire · 69d ago
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
Business Wire · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.